mhurhangee/ep-ind-claims huggingface dataset:
A diagnostic apparatus for diagnosing a home appliance in response to a signal, comprising a plurality of frequencies, received from the home appliance, the diagnostic apparatus comprising: a signal processing unit arranged to extract product information from the signal by dividing the signal into a plurality of signal symbols, having a symbol time, and determining a bit value associated with the signal in each signal symbol; a diagnosing unit arranged to diagnose the home appliance by analyzing the product information and outputting a status of the home appliance; and a control unit arranged to output explanations for the diagnosis of the home appliance and a diagnosis result; wherein the signal processing unit is further arranged to determine that an error occurred and extract the product information again after increasing or decreasing a first symbol time, until an error check result indicates that signal conversion was successful. a signal processing unit arranged to extract product information from the signal by dividing the signal into a plurality of signal symbols, having a symbol time, and determining a bit value associated with the signal in each signal symbol; a diagnosing unit arranged to diagnose the home appliance by analyzing the product information and outputting a status of the home appliance; and a control unit arranged to output explanations for the diagnosis of the home appliance and a diagnosis result; wherein the signal processing unit is further arranged to determine that an error occurred and extract the product information again after increasing or decreasing a first symbol time, until an error check result indicates that signal conversion was successful.
An X-ray fluorescence spectrometer comprising: an X-ray source configured to irradiate a sample with primary X-rays; a light condensing device configured to condense the primary X-rays emitted from the X-ray source to reduce an irradiation area on the sample; a detector configured to detect fluorescent X-rays produced from the sample irradiated with the primary X-rays; a housing which accommodates at least the X-ray source and the light condensing device; a temperature sensor which is disposed in at least one of the X-ray source and a periphery of the X-ray source; characterized by at least one external-air fan, which is disposed on the housing, and which is configured to exchange internal air with external air; and a control section configured to drive the external-air fan based on temperature information detected by the temperature sensor so as to adjust an ambient temperature around the X-ray source to a constant temperature that is higher than a temperature of external air around the spectrometer. an X-ray source configured to irradiate a sample with primary X-rays; a light condensing device configured to condense the primary X-rays emitted from the X-ray source to reduce an irradiation area on the sample; a detector configured to detect fluorescent X-rays produced from the sample irradiated with the primary X-rays; a housing which accommodates at least the X-ray source and the light condensing device; a temperature sensor which is disposed in at least one of the X-ray source and a periphery of the X-ray source; characterized by at least one external-air fan, which is disposed on the housing, and which is configured to exchange internal air with external air; and a control section configured to drive the external-air fan based on temperature information detected by the temperature sensor so as to adjust an ambient temperature around the X-ray source to a constant temperature that is higher than a temperature of external air around the spectrometer.
A method of at least one of maintaining and restoring the viability of at least one ex-vivo organ subjected to a period of ischemia or hypoxia, comprising: perfusing said at least one organ with a first medical fluid at a first temperature to reduce or stop catabolic changes in the organ, the first temperature being a hypothermic temperature from 4 to 10°C; perfusing said at least one organ with a second medical fluid at a second temperature to at least one of store and transport the organ, the second temperature being a normothermic temperature from 12 to 24°C, and further perfusing said at least one organ having been perfused with the second medical fluid with a third medical fluid at a third temperature, which is a normothermic temperature that is higher than the second temperature and which is from 24°C to 37°C, wherein the organ is not returned to the donor. perfusing said at least one organ with a first medical fluid at a first temperature to reduce or stop catabolic changes in the organ, the first temperature being a hypothermic temperature from 4 to 10°C; perfusing said at least one organ with a second medical fluid at a second temperature to at least one of store and transport the organ, the second temperature being a normothermic temperature from 12 to 24°C, and further perfusing said at least one organ having been perfused with the second medical fluid with a third medical fluid at a third temperature, which is a normothermic temperature that is higher than the second temperature and which is from 24°C to 37°C, wherein the organ is not returned to the donor.
A device to control one or more window shading devices (130-135,370,371) in a room, the device comprising: - one or more input ports configured to receive one or more temperature setpoints (T set), measurements (T in) from a temperature sensor inside the room, and values of an outdoor temperature (T out) outside the room; - an output port configured to send commands to the one or more window shading devices; - a processing logic configured to calculate commands to define one or more states of said one or more window shading devices (130-135,370,371) based on said one or more temperature setpoints (T set), said measurements (T in), said values (T out) and a room temperature model, characterized in that the room temperature model comprises parameters representative of: - a thermal capacity of the room; - a heat transfer coefficient between the inside and the outside of the room and - timed predictions of solar radiation. - one or more input ports configured to receive one or more temperature setpoints (T set), measurements (T in) from a temperature sensor inside the room, and values of an outdoor temperature (T out) outside the room; - an output port configured to send commands to the one or more window shading devices; - a processing logic configured to calculate commands to define one or more states of said one or more window shading devices (130-135,370,371) based on said one or more temperature setpoints (T set), said measurements (T in), said values (T out) and a room temperature model, - a thermal capacity of the room; - a heat transfer coefficient between the inside and the outside of the room and - timed predictions of solar radiation.
A surgical drape comprising: a mainsheet, the mainsheet having a transverse width, the mainsheet having a fenestration therein permitting access to a surgical region for performance of a surgical procedure when the drape covers a patient during the surgical procedure, the mainsheet having a head region for placement proximal a head of a patient during the surgical procedure and having a surgeon-facing side and a patient facing side; a substantially transparent sheet having a surgeon-facing side and a patient-facing side, the substantially transparent sheet extending across the entire width of the surgical drape and joined to the mainsheet at said head region for providing the patient with visual access therethrough; and a substantially opaque screen attached to the patient-facing side of the substantially transparent sheet and effective to occlude the patient's visual access through the substantially transparent sheet, said substantially opaque screen being at least partially removable from said substantially transparent sheet to thereby permit the patient's visual access through the substantially transparent sheet, said opaque screen partially covering the transparent sheet. a mainsheet, the mainsheet having a transverse width, the mainsheet having a fenestration therein permitting access to a surgical region for performance of a surgical procedure when the drape covers a patient during the surgical procedure, the mainsheet having a head region for placement proximal a head of a patient during the surgical procedure and having a surgeon-facing side and a patient facing side; a substantially transparent sheet having a surgeon-facing side and a patient-facing side, the substantially transparent sheet extending across the entire width of the surgical drape and joined to the mainsheet at said head region for providing the patient with visual access therethrough; and a substantially opaque screen attached to the patient-facing side of the substantially transparent sheet and effective to occlude the patient's visual access through the substantially transparent sheet, said substantially opaque screen being at least partially removable from said substantially transparent sheet to thereby permit the patient's visual access through the substantially transparent sheet, said opaque screen partially covering the transparent sheet.
A system for locating a first target nerve associated with a facet joint via nerve stimulation and monitoring of electrical muscle activity in a multifidus muscle adjacent the first target nerve, the multifidus muscle comprising a medial fascicle, an intermediate fascicle, and a lateral fascicle, wherein the system comprises: a first probe comprising an insulated shaft and a first probe electrode located at a distal end of the shaft, wherein the first probe is housed within a first cannula; a first recording electrode for monitoring electrical muscle activity in the medial fascicle of the multifidus muscle, wherein the first recording electrode is configured for placement in the medial fascicle of the multifidus muscle, wherein the first recording electrode is disposed on the first cannula; a signal generator; and a controller coupled to the first probe electrode and the first recording electrode, wherein the controller delivers a first nerve stimulation from the signal generator to the first target nerve via the first probe electrode, wherein the controller monitors electrical muscle activity in the medial fascicle via the first recording electrode, wherein proximity of the first probe to the first target nerve is determined by the electrical muscle activity in the medial fascicle elicited as a result of the first nerve stimulation, wherein the controller provides feedback to a user to guide placement of the first probe adjacent the first target nerve. a first probe comprising an insulated shaft and a first probe electrode located at a distal end of the shaft, wherein the first probe is housed within a first cannula; a first recording electrode for monitoring electrical muscle activity in the medial fascicle of the multifidus muscle, wherein the first recording electrode is configured for placement in the medial fascicle of the multifidus muscle, wherein the first recording electrode is disposed on the first cannula; a signal generator; and a controller coupled to the first probe electrode and the first recording electrode, wherein the controller delivers a first nerve stimulation from the signal generator to the first target nerve via the first probe electrode, wherein the controller monitors electrical muscle activity in the medial fascicle via the first recording electrode, wherein proximity of the first probe to the first target nerve is determined by the electrical muscle activity in the medial fascicle elicited as a result of the first nerve stimulation, wherein the controller provides feedback to a user to guide placement of the first probe adjacent the first target nerve.
A cooling system for molding fixtures, and particularly for foundry molds, comprising: - water treatment means - compressed air generation means - means for pressurizing the treated water - a device for mixing air with said treated water and for the controlled ejection of atomized water under pressure toward a cooling circuit of a molding fixture; characterized in that: - said compressed air generation means comprise a compressed air system, a branch of which has a pressure reduction device, with a solenoid control valve upstream; - said mixing and ejection device comprises a pneumatic valve that actuates the opening of the water circuit, such as the line connected to the water pressurization means, said pneumatic valve being actuated by the passage of the air between the solenoid control valve of the compressed air generation means and the air pressure reduction device. - water treatment means - compressed air generation means - means for pressurizing the treated water - a device for mixing air with said treated water and for the controlled ejection of atomized water under pressure toward a cooling circuit of a molding fixture; - said compressed air generation means comprise a compressed air system, a branch of which has a pressure reduction device, with a solenoid control valve upstream; - said mixing and ejection device comprises a pneumatic valve that actuates the opening of the water circuit, such as the line connected to the water pressurization means, said pneumatic valve being actuated by the passage of the air between the solenoid control valve of the compressed air generation means and the air pressure reduction device.
A vulcanized rubber composition for a tread comprising: 1 to 20 parts by mass of an ethylene-propylene-styrene copolymer and 60 parts by mass or more of a filler based on 100 parts by mass of a rubber component comprising 20 to 50% by mass of a butadiene rubber and 30 to 80% by mass of a styrene butadiene rubber, wherein the filler comprises silica and 20 to 120 parts by mass of a carbon black having a nitrogen adsorption specific surface area of not less than 100 m 2 /g, and wherein an elongation at break of the vulcanized rubber composition is not less than 300% in the atmosphere of 180°C according to JIS K 6251: 2017. 1 to 20 parts by mass of an ethylene-propylene-styrene copolymer and 60 parts by mass or more of a filler based on 100 parts by mass of a rubber component comprising 20 to 50% by mass of a butadiene rubber and 30 to 80% by mass of a styrene butadiene rubber, wherein the filler comprises silica and 20 to 120 parts by mass of a carbon black having a nitrogen adsorption specific surface area of not less than 100 m 2 /g, and wherein an elongation at break of the vulcanized rubber composition is not less than 300% in the atmosphere of 180°C according to JIS K 6251: 2017.
An implantable medical device, comprising: a stent having a covered portion and an uncovered portion; wherein the covered portion is releasably attached to the uncovered portion; a cover member disposed along the covered portion; wherein the uncovered portion includes a release tab that is designed to release the uncovered portion from the covered portion; and a removal member coupled to the covered portion for aiding in the removal of the covered portion from an implantation site. a stent having a covered portion and an uncovered portion; wherein the covered portion is releasably attached to the uncovered portion; a cover member disposed along the covered portion; wherein the uncovered portion includes a release tab that is designed to release the uncovered portion from the covered portion; and a removal member coupled to the covered portion for aiding in the removal of the covered portion from an implantation site.
An information processing apparatus comprising: a heartbeat sensor configured to measure heartbeat of a user; an acceleration sensor configured to detect acceleration; a position information detection device configured to detect position information; a warning issuing device (29, 37) configured to issue a warning; a storage device configured to hold a first cycle based on transition times of sleep depths for one cycle; and a processor configured to detect boarding of the user on a conveyance on the basis of the acceleration, to activate the heartbeat sensor when the boarding has been detected, to detect a transition to sleep of the user and a transition time to the sleep on the basis of heartbeat measured by the heartbeat sensor, to stop driving of the heartbeat sensor when the transition has been detected, and to make the warning issuing device issue a warning when it has been determined that a distance between a position represented by the position information detected by the position information detection device and a destination is shorter than a prescribed value and that a sleep depth of the user is shallow on the basis of the first cycle and a transition time to the sleep. a heartbeat sensor configured to measure heartbeat of a user; an acceleration sensor configured to detect acceleration; a position information detection device configured to detect position information; a warning issuing device (29, 37) configured to issue a warning; a storage device configured to hold a first cycle based on transition times of sleep depths for one cycle; and a processor configured to detect boarding of the user on a conveyance on the basis of the acceleration, to activate the heartbeat sensor when the boarding has been detected, to detect a transition to sleep of the user and a transition time to the sleep on the basis of heartbeat measured by the heartbeat sensor, to stop driving of the heartbeat sensor when the transition has been detected, and to make the warning issuing device issue a warning when it has been determined that a distance between a position represented by the position information detected by the position information detection device and a destination is shorter than a prescribed value and that a sleep depth of the user is shallow on the basis of the first cycle and a transition time to the sleep.
An immunomodulator composition, wherein the immunomodulator composition comprises: a. a cationic liposome delivery vehicle; and b. a nucleic acid molecule, wherein the nucleic acid molecule is an isolated bacterially-derived nucleic acid vector without a gene insert, or a fragment thereof, for use in increasing the hatchability of an embryonated chicken egg challenged with Escherichia coli by administration in ovo to the egg from 0.05 to 10 micrograms of the immunomodulator composition. a. a cationic liposome delivery vehicle; and b. a nucleic acid molecule, wherein the nucleic acid molecule is an isolated bacterially-derived nucleic acid vector without a gene insert, or a fragment thereof,
Screw press for separating filtrate from a feed material, comprising a feed area, a dewatering area and a discharge area, where the feed material can be fed to the screw press via the feed area, the dewatering area comprises a pressing screw arranged in a filter drum so as to be rotatable around an axis of rotation and, by rotation of the pressing screw, the feed material can be fed from the feed area via the dewatering area to the discharge area, where the feed material is guided in the dewatering area between the filter drum and the pressing screw, the filtrate can be separated through the filter drum, and a sensor arrangement comprising a sensor for measuring the filtrate content is arranged in the discharge area, where the feed material can flow against and/or around the sensor, characterised in that a pressure acting on the sensor from the feed material can be compensated via the sensor arrangement, where the sensor arrangement comprises a guide and the sensor can be moved by means of the guide in the discharge area to compensate for the pressure acting on the sensor from the feed material.
A savoury concentrate comprising the following components: a) 22-85 wt.% inorganic salt; b) 2-60 wt.% fat; c) 1.5-10 wt.% of heteropolysaccharide gum selected from guar gum, locust bean gum, cassia gum, tara gum, konjac gum and combinations thereof; d) 0-25 wt.% of glutamate component selected from glutamic acid, edible glutamate salts and combinations thereof; e) 0-25 w.% starch component selected from native starch, pregelatinised starch, maltodextrin, modified starch and combinations thereof; f) 0-20 wt.% of sugar selected from monosaccharides, disaccharides and combinations thereof; g) 0-45 wt.% of vegetable matter selected from vegetables, herbs, spices and combinations thereof; h) 0-10 wt.% water; wherein the components a) to e) together constitute at least 55 wt.% of the savoury concentrate and wherein the components a) to h) together constitute at least 75 wt.% of the savoury concentrate. a) 22-85 wt.% inorganic salt; b) 2-60 wt.% fat; c) 1.5-10 wt.% of heteropolysaccharide gum selected from guar gum, locust bean gum, cassia gum, tara gum, konjac gum and combinations thereof; d) 0-25 wt.% of glutamate component selected from glutamic acid, edible glutamate salts and combinations thereof; e) 0-25 w.% starch component selected from native starch, pregelatinised starch, maltodextrin, modified starch and combinations thereof; f) 0-20 wt.% of sugar selected from monosaccharides, disaccharides and combinations thereof; g) 0-45 wt.% of vegetable matter selected from vegetables, herbs, spices and combinations thereof; h) 0-10 wt.% water;
A method for identifying a cancer patient who is (a) likely to, or (b) less likely to, respond to treatment with a c-met antagonist comprising the step of determining whether the patient's cancer has (a) a high amount or (b) a low amount of c-met biomarker, wherein the c-met biomarker expression indicates that the patient is (a) likely to respond to treatment with the c-met antagonist, or (b) less likely to respond to treatment with the c-met antagonist, wherein c-met biomarker protein expression is determined in a cancer sample obtained from the patient using immunohistochemistry and (a) high c-met biomarker expression is (i) 50% or more of the tumor cells with moderate c-met staining intensity or combined moderate/strong c-met staining intensity but less than 50% of the tumor cells with strong staining intensity (IHC score 2), or (ii) 50% or more of the tumor cells with strong c-met staining intensity (IHC score 3), and (b) low c-met biomarker expression is (i) negative c-met staining, less than 50% of tumor cells with weak or combined weak and moderate c-met staining intensity (IHC score 0), or (ii) 50% or more tumor cells with weak or combined weak and moderate c-met staining intensity but less than 50% tumor cells with moderate or combined moderate and strong c-met staining intensity (IHC score 1), wherein c-met expression staining intensity is determined relative to c-met staining intensity of control cell pellets, and wherein a control for moderate c-met staining intensity has the c-met staining intensity of cell line A549; a control for strong c-met staining intensity has the c-met staining intensity of cell line H441; a control for negative c-met staining intensity has the c-met staining intensity of cell line H1155; and a control for weak c-met staining intensity has the c-met staining intensity of cell line HEK-293.